vs

Side-by-side financial comparison of MIMEDX GROUP, INC. (MDXG) and Origin Bancorp, Inc. (OBK). Click either name above to swap in a different company.

MIMEDX GROUP, INC. is the larger business by last-quarter revenue ($118.1M vs $104.0M, roughly 1.1× Origin Bancorp, Inc.). Origin Bancorp, Inc. runs the higher net margin — 26.6% vs 12.9%, a 13.8% gap on every dollar of revenue. Over the past eight quarters, MIMEDX GROUP, INC.'s revenue compounded faster (18.1% CAGR vs 3.9%).

MiMedx is an American biomedical company based in Marietta, Georgia, founded in 2008. Using tissues from birth such as the placenta, amniotic sac, and umbilical cord, MiMedx creates skin for skin grafts for medical use.

Southern Bancorp is a community development financial institution headquartered in Arkadelphia, Arkansas. It was founded in 1986 as Southern Development Bancorporation, and is often referred to simply as "Southern".

MDXG vs OBK — Head-to-Head

Bigger by revenue
MDXG
MDXG
1.1× larger
MDXG
$118.1M
$104.0M
OBK
Higher net margin
OBK
OBK
13.8% more per $
OBK
26.6%
12.9%
MDXG
Faster 2-yr revenue CAGR
MDXG
MDXG
Annualised
MDXG
18.1%
3.9%
OBK

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
MDXG
MDXG
OBK
OBK
Revenue
$118.1M
$104.0M
Net Profit
$15.2M
$27.7M
Gross Margin
83.9%
Operating Margin
17.8%
Net Margin
12.9%
26.6%
Revenue YoY
27.1%
Net Profit YoY
104.2%
EPS (diluted)
$0.10
$0.89

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MDXG
MDXG
OBK
OBK
Q1 26
$104.0M
Q4 25
$118.1M
$103.4M
Q3 25
$113.7M
$109.8M
Q2 25
$98.6M
$83.5M
Q1 25
$88.2M
$94.1M
Q4 24
$92.9M
$78.3M
Q3 24
$84.1M
$90.8M
Q2 24
$87.2M
$96.4M
Net Profit
MDXG
MDXG
OBK
OBK
Q1 26
$27.7M
Q4 25
$15.2M
$29.5M
Q3 25
$16.7M
$8.6M
Q2 25
$9.6M
$14.6M
Q1 25
$7.0M
$22.4M
Q4 24
$7.4M
$14.3M
Q3 24
$8.1M
$18.6M
Q2 24
$17.6M
$21.0M
Gross Margin
MDXG
MDXG
OBK
OBK
Q1 26
Q4 25
83.9%
Q3 25
83.5%
Q2 25
81.1%
Q1 25
81.2%
Q4 24
81.8%
Q3 24
81.8%
Q2 24
83.0%
Operating Margin
MDXG
MDXG
OBK
OBK
Q1 26
Q4 25
17.8%
36.2%
Q3 25
19.5%
10.0%
Q2 25
12.5%
22.3%
Q1 25
9.4%
30.4%
Q4 24
11.9%
23.0%
Q3 24
13.3%
26.1%
Q2 24
26.9%
27.7%
Net Margin
MDXG
MDXG
OBK
OBK
Q1 26
26.6%
Q4 25
12.9%
28.5%
Q3 25
14.7%
7.9%
Q2 25
9.8%
17.5%
Q1 25
8.0%
23.8%
Q4 24
8.0%
18.2%
Q3 24
9.6%
20.5%
Q2 24
20.2%
21.8%
EPS (diluted)
MDXG
MDXG
OBK
OBK
Q1 26
$0.89
Q4 25
$0.10
$0.95
Q3 25
$0.11
$0.27
Q2 25
$0.06
$0.47
Q1 25
$0.05
$0.71
Q4 24
$0.05
$0.45
Q3 24
$0.05
$0.60
Q2 24
$0.12
$0.67

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MDXG
MDXG
OBK
OBK
Cash + ST InvestmentsLiquidity on hand
$166.1M
Total DebtLower is stronger
$18.0M
Stockholders' EquityBook value
$256.5M
$1.3B
Total Assets
$342.7M
$10.2B
Debt / EquityLower = less leverage
0.07×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MDXG
MDXG
OBK
OBK
Q1 26
Q4 25
$166.1M
$424.2M
Q3 25
$142.1M
$626.9M
Q2 25
$118.9M
$334.1M
Q1 25
$106.4M
$486.2M
Q4 24
$104.4M
$470.2M
Q3 24
$88.8M
$321.2M
Q2 24
$69.0M
$288.1M
Total Debt
MDXG
MDXG
OBK
OBK
Q1 26
Q4 25
$18.0M
Q3 25
Q2 25
Q1 25
Q4 24
$19.0M
Q3 24
Q2 24
Stockholders' Equity
MDXG
MDXG
OBK
OBK
Q1 26
$1.3B
Q4 25
$256.5M
$1.2B
Q3 25
$238.9M
$1.2B
Q2 25
$216.6M
$1.2B
Q1 25
$202.8M
$1.2B
Q4 24
$193.1M
$1.1B
Q3 24
$181.0M
$1.1B
Q2 24
$168.0M
$1.1B
Total Assets
MDXG
MDXG
OBK
OBK
Q1 26
$10.2B
Q4 25
$342.7M
$9.7B
Q3 25
$319.0M
$9.8B
Q2 25
$291.1M
$9.7B
Q1 25
$270.4M
$9.8B
Q4 24
$263.9M
$9.7B
Q3 24
$243.9M
$10.0B
Q2 24
$230.2M
$9.9B
Debt / Equity
MDXG
MDXG
OBK
OBK
Q1 26
Q4 25
0.07×
Q3 25
Q2 25
Q1 25
Q4 24
0.10×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MDXG
MDXG
OBK
OBK
Operating Cash FlowLast quarter
$25.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.64×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MDXG
MDXG
OBK
OBK
Q1 26
Q4 25
$25.0M
$158.9M
Q3 25
$29.3M
$59.3M
Q2 25
$14.4M
$20.6M
Q1 25
$5.3M
$35.6M
Q4 24
$18.8M
$108.5M
Q3 24
$19.6M
$39.6M
Q2 24
$21.8M
$11.9M
Free Cash Flow
MDXG
MDXG
OBK
OBK
Q1 26
Q4 25
$151.1M
Q3 25
$56.8M
Q2 25
$19.6M
Q1 25
$34.8M
Q4 24
$86.4M
Q3 24
$32.2M
Q2 24
$6.5M
FCF Margin
MDXG
MDXG
OBK
OBK
Q1 26
Q4 25
146.0%
Q3 25
51.7%
Q2 25
23.5%
Q1 25
37.0%
Q4 24
110.3%
Q3 24
35.5%
Q2 24
6.8%
Capex Intensity
MDXG
MDXG
OBK
OBK
Q1 26
Q4 25
7.6%
Q3 25
2.3%
Q2 25
1.2%
Q1 25
0.8%
Q4 24
28.1%
Q3 24
8.1%
Q2 24
5.6%
Cash Conversion
MDXG
MDXG
OBK
OBK
Q1 26
Q4 25
1.64×
5.38×
Q3 25
1.75×
6.88×
Q2 25
1.50×
1.41×
Q1 25
0.75×
1.59×
Q4 24
2.53×
7.60×
Q3 24
2.42×
2.13×
Q2 24
1.24×
0.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MDXG
MDXG

Wound$78.7M67%
Surgical$39.4M33%

OBK
OBK

Net Interest Income$87.2M84%
Noninterest Income$16.8M16%

Related Comparisons